Access count of this item: 952

Files in This Item:
File Description SizeFormat 
59_277.pdf933.47 kBAdobe PDFView/Open
Title: 浸潤性膀胱癌に対する術前抗癌化学療法としてのGC療法とMVAC療法の比較
Other Titles: Relative Efficacy of Neoadjuvant Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Adriamycin, and Cisplatin in the Management for Muscle-Invasive Bladder Cancer
Authors: 川村, 憲彦  KAKEN_name
松下, 慎  KAKEN_name
岡田, 宜之  KAKEN_name
氏家, 剛  KAKEN_name
任, 幹夫  KAKEN_name
辻畑, 正雄  KAKEN_name
Author's alias: Kawamura, Norihiko
Matsushita, Makoto
Okada, Takayuki
Ujike, Takeshi
Nin, Mikio
Tsujihata, Masao
Keywords: Neoadjuvantchemot herapy
Bladder cancer
Issue Date: May-2013
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 59
Issue: 5
Start page: 277
End page: 281
Abstract: Systemic cisplatin-based chemotherapy regimens are the gold standard in advanced bladder cancer. Gemcitabine plus cisplatin (GC) therapy has often been used, although there is no significant evidence that it is better than methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) therapy in neoadjuvant chemotherapy. We retrospectively evaluated the relative efficacy of the two chemotherapeutic regimens in the management of muscle-invasive bladder cancer on patients who had had radical cystectomy for clinical stage T2-T4, N and, M0 bladder cancer. Fourteen patients (24.1%) and 44 (75.9%) patients were treated with GC and MVAC therapy, respectively. GC therapy was significantly more effective than MVAC therapy in pathological down-staging (to pT0) rate. On multivariate analysis, the choice of regimen (MVAC) was an independent predictor of the presence of residual cancer after a neoadjuvant chemotherapy. The clinical response to neoadjuvant GC therapy was superior to that to neoadjuvant MVAC therapy. Moreover, GC therapy was associated with less non-hematologic toxicity than MVAC therapy, especially with respect to the occurrence of nausea.
Rights: 許諾条件により本文は2014-06-01に公開
PubMed ID: 23719134
Appears in Collections:Vol.59 No.5

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.